These PROTACs are capable of efficiently degrading NPM-ALK in lymphoma as well as EML4-ALK fusion proteins in NSCLC cells in association with a marked inhibition of cell growth (Kang et al., 2018; Zhang et al., 2018). This evidence concerns the gene ALK and non-small cell lung carcinoma.